JP2023539056A5 - - Google Patents
Info
- Publication number
- JP2023539056A5 JP2023539056A5 JP2023509799A JP2023509799A JP2023539056A5 JP 2023539056 A5 JP2023539056 A5 JP 2023539056A5 JP 2023509799 A JP2023509799 A JP 2023509799A JP 2023509799 A JP2023509799 A JP 2023509799A JP 2023539056 A5 JP2023539056 A5 JP 2023539056A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- population
- antigen
- concentration
- peptide antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063065327P | 2020-08-13 | 2020-08-13 | |
| US63/065,327 | 2020-08-13 | ||
| PCT/US2021/045800 WO2022036137A1 (en) | 2020-08-13 | 2021-08-12 | T cell manufacturing compositions and methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023539056A JP2023539056A (ja) | 2023-09-13 |
| JP2023539056A5 true JP2023539056A5 (https=) | 2024-08-21 |
Family
ID=80248187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023509799A Pending JP2023539056A (ja) | 2020-08-13 | 2021-08-12 | Ｔ細胞を製造する組成物および方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230374455A1 (https=) |
| EP (1) | EP4196135A4 (https=) |
| JP (1) | JP2023539056A (https=) |
| KR (1) | KR20230074719A (https=) |
| CN (1) | CN116710551A (https=) |
| AU (1) | AU2021325081A1 (https=) |
| BR (1) | BR112023002733A2 (https=) |
| CA (1) | CA3189285A1 (https=) |
| CL (1) | CL2023000437A1 (https=) |
| CO (1) | CO2023002953A2 (https=) |
| CU (1) | CU20230011A7 (https=) |
| IL (1) | IL300564A (https=) |
| MX (1) | MX2023001815A (https=) |
| WO (1) | WO2022036137A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202004116QA (en) | 2017-11-08 | 2020-06-29 | Biontech Us Inc | T cell manufacturing compositions and methods |
| CN119317705A (zh) * | 2022-02-15 | 2025-01-14 | 马克治疗公司 | 用于抗原特异性t细胞扩增的组合物和方法 |
| CA3254900A1 (en) * | 2022-03-30 | 2023-10-05 | Mdx Management Llc | COMPOSITIONS AND METHODS FOR ACTIVATING IMMUNE CELLS |
| WO2024260318A1 (zh) * | 2023-06-19 | 2024-12-26 | 苏州沙砾生物科技有限公司 | 一种肿瘤特异性细胞的富集方法和应用 |
| WO2025245488A2 (en) * | 2024-05-24 | 2025-11-27 | Biontech Us Inc. | Compositions and methods for t cell manufacturing and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9022788D0 (en) | 1990-10-19 | 1990-12-05 | Cortecs Ltd | Pharmaceutical formulations |
| WO1994003205A1 (en) | 1992-08-07 | 1994-02-17 | Cytel Corporation | Hla binding peptides and their uses |
| BR9406652A (pt) | 1993-03-05 | 1996-09-10 | Cytel Corp | Composição |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| EP2569633B1 (en) | 2010-05-14 | 2016-02-10 | The General Hospital Corporation | Compositions and methods of identifying tumor specific neoantigens |
| KR20230076867A (ko) | 2013-12-20 | 2023-05-31 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신생항원 백신과의 병용 요법 |
| AU2017254477A1 (en) | 2016-04-18 | 2018-11-01 | Jennifer G. ABELIN | Improved HLA epitope prediction |
| SG11202004116QA (en) * | 2017-11-08 | 2020-06-29 | Biontech Us Inc | T cell manufacturing compositions and methods |
| EP3844265A2 (en) * | 2018-08-31 | 2021-07-07 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
| AR118859A1 (es) * | 2019-05-08 | 2021-11-03 | Neon Therapeutics Inc | Composiciones y métodos de fabricación de células t |
-
2021
- 2021-08-12 MX MX2023001815A patent/MX2023001815A/es unknown
- 2021-08-12 AU AU2021325081A patent/AU2021325081A1/en active Pending
- 2021-08-12 BR BR112023002733A patent/BR112023002733A2/pt unknown
- 2021-08-12 US US18/007,024 patent/US20230374455A1/en active Pending
- 2021-08-12 IL IL300564A patent/IL300564A/en unknown
- 2021-08-12 CN CN202180070338.2A patent/CN116710551A/zh active Pending
- 2021-08-12 CU CU2023000011A patent/CU20230011A7/es unknown
- 2021-08-12 CA CA3189285A patent/CA3189285A1/en active Pending
- 2021-08-12 WO PCT/US2021/045800 patent/WO2022036137A1/en not_active Ceased
- 2021-08-12 KR KR1020237008593A patent/KR20230074719A/ko active Pending
- 2021-08-12 JP JP2023509799A patent/JP2023539056A/ja active Pending
- 2021-08-12 EP EP21856741.0A patent/EP4196135A4/en active Pending
-
2023
- 2023-02-10 CL CL2023000437A patent/CL2023000437A1/es unknown
- 2023-03-10 CO CONC2023/0002953A patent/CO2023002953A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023539056A5 (https=) | ||
| Morotti et al. | Promises and challenges of adoptive T-cell therapies for solid tumours | |
| Kusnadi et al. | Severely ill patients with COVID-19 display impaired exhaustion features in SARS-CoV-2–reactive CD8+ T cells | |
| Meng et al. | Empirical identification and validation of tumor-targeting T cell receptors from circulation using autologous pancreatic tumor organoids | |
| Mei et al. | Siglec-9 acts as an immune-checkpoint molecule on macrophages in glioblastoma, restricting T-cell priming and immunotherapy response | |
| Prokhnevska et al. | CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor | |
| Novak et al. | MHC class II tetramers identify peptide-specific human CD4+ T cells proliferating in response to influenza A antigen | |
| Monsurro et al. | Functional heterogeneity of vaccine-induced CD8+ T cells | |
| Suhoski et al. | Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules | |
| Wölfl et al. | Antigen-specific activation and cytokine-facilitated expansion of naive, human CD8+ T cells | |
| JP2024041873A5 (https=) | ||
| JP6815992B2 (ja) | キメラ抗原受容体療法に対する治療応答性を予測するバイオマーカーおよびその使用 | |
| Coleman et al. | Recovery of CD8+ T-cell function during systemic chemotherapy in advanced ovarian cancer | |
| Romero et al. | Novel methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapy | |
| BR112021003305A2 (pt) | métodos para produzir células que expressam receptor de antígeno quimérico | |
| Kast et al. | Advances in identification and selection of personalized neoantigen/T-cell pairs for autologous adoptive T cell therapies | |
| Ali et al. | T cells targeted to TdT kill leukemic lymphoblasts while sparing normal lymphocytes | |
| Borgers et al. | Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial | |
| CN109715788A (zh) | 用于免疫疗法的t细胞组合物 | |
| Giannakopoulou et al. | AT cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivo | |
| Saillard et al. | Impact of immunotherapy on CD4 T cell phenotypes and function in cancer | |
| Chatani et al. | Cell surface marker-based capture of neoantigen-reactive CD8+ T-cell receptors from metastatic tumor digests | |
| JP2025163198A (ja) | キメラサイトカイン受容体 | |
| JP2022522802A (ja) | Ｔ細胞受容体の選択 | |
| Wölfl et al. | Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy |